C

Caliway Biopharmaceuticals Co Ltd
TWSE:6919

Watchlist Manager
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
Watchlist
Price: 153.5 TWD -0.97% Market Closed
Market Cap: 238.1B TWD

Income Statement

Earnings Waterfall
Caliway Biopharmaceuticals Co Ltd

Revenue
34.6m TWD
Cost of Revenue
-10.6m TWD
Gross Profit
23.9m TWD
Operating Expenses
-738.9m TWD
Operating Income
-715m TWD
Other Expenses
226.3m TWD
Net Income
-488.7m TWD

Income Statement
Caliway Biopharmaceuticals Co Ltd

Rotate your device to view
Income Statement
Currency: TWD
Dec-2022 Jun-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
1
0
0
0
0
0
0
0
0
0
Revenue
13
N/A
28
+118%
39
+39%
43
+11%
36
-17%
59
+65%
44
-25%
40
-9%
45
+11%
35
-23%
Gross Profit
Cost of Revenue
(3)
(8)
(11)
(13)
(10)
(18)
(14)
(12)
(14)
(11)
Gross Profit
10
N/A
20
+106%
27
+39%
30
+11%
5
-83%
21
+305%
31
+45%
28
-9%
31
+10%
24
-23%
Operating Income
Operating Expenses
(329)
(488)
(541)
(785)
(700)
(868)
(748)
(731)
(697)
(739)
Selling, General & Administrative
(34)
(32)
(37)
(48)
(56)
(92)
(98)
(112)
(161)
(91)
Research & Development
(295)
(455)
(504)
0
(175)
(309)
(650)
(619)
(536)
0
Other Operating Expenses
0
0
0
(736)
(468)
(468)
0
0
0
(648)
Operating Income
(320)
N/A
(468)
-46%
(513)
-10%
(754)
-47%
(675)
+10%
(828)
-23%
(717)
+13%
(704)
+2%
(667)
+5%
(715)
-7%
Pre-Tax Income
Interest Income Expense
19
24
16
0
18
22
113
144
306
0
Gain/Loss on Disposition of Assets
(0)
0
0
0
0
0
0
0
0
0
Total Other Income
15
15
9
48
35
46
16
14
(258)
226
Pre-Tax Income
(286)
N/A
(429)
-50%
(488)
-14%
(706)
-45%
(622)
+12%
(760)
-22%
(589)
+23%
(547)
+7%
(619)
-13%
(489)
+21%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
0
0
Income from Continuing Operations
(286)
(429)
(488)
(706)
(622)
(760)
(589)
(547)
(619)
(489)
Net Income (Common)
(286)
N/A
(429)
-50%
(488)
-14%
(706)
-45%
(622)
+12%
(760)
-22%
(589)
+23%
(547)
+7%
(619)
-13%
(489)
+21%
EPS (Diluted)
-4.64
N/A
-6.95
-50%
-0.39
+94%
-5.08
-1 203%
-4.47
+12%
-0.54
+88%
-0.41
+24%
-0.35
+15%
-0.41
-17%
-0.32
+22%